pms-Sumatriptan

Sumatriptan succinate.

Each tablet contains 50 mg sumatriptan (base) as the succinate salt.
Proper name: Sumatriptan succinate (USAN, BAN and INN).
Chemical name: 3-[2-(dimethyl amino)ethyl]-N-methyl-1H-Indole-5-methane sulphonamide, butane-1,4-dioate (1:1).
Molecular formula: C₁₄H₂₁N₃O₂S·C₄H₆O₄.
Molecular mass: 413.5 g/mol.
Physicochemical properties: Sumatriptan succinate is a white to off-white powder with a melting point between 164.6 °C-165.5 °C.
Solubility: In water (4 °C) = 54 mg/mL.
In water (20 °C) = 101 mg/mL.
In saline (0.9% w/v, 4 °C) = 62 mg/mL.
In saline (0.9% w/v, 20 °C) = 109 mg/mL.
pH and pka: The pH of a 1% w/v solution of sumatriptan succinate in water is approximately 4.9.
pka1 (succinic acid) = 4.21, 5.67.
pka2 (3° amine group) = 9.63.
pka3 (sulphonamide group) = > 12.
Partition coefficient (between n-octanol and water): log P = 1.07 at a pH of 10.7.
Excipients/Inactive Ingredients: Colloidal Silicon Dioxide, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene glycol, Polyvinyl Alcohol, Sodium Starch Glycolate, Talc and Titanium Dioxide.

Pharmacology: Mechanism of Action: Sumatriptan succinate has been shown to be effective in relieving migraine headache. Sumatriptan is an agonist for a vascular 5-hydroxytryptamine_1D (5-HT_1D) receptor subtype (a member of the 5-HT₁ family), and has only weak affinity for 5-HT_1A receptors and no significant activity (as measured using standard radioligand binding assays) or pharmacological activity at 5-HT₂, 5-HT₃, 5-HT₄, 5-HT_5A, or 5-HT₇ receptor subtypes, or at alpha₁-, alpha₂-, or beta-adrenergic; dopamine₁ or dopamine₂; muscarinic; or benzodiazepine receptors.
The therapeutic activity of sumatriptan succinate in migraine is generally attributed to its agonist activity at 5-HT_1B/5-HT_1D receptors. Two current theories have been proposed to explain the efficacy of 5-HT₁ receptor agonists in migraine. One theory suggests that activation of 5-HT₁ receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is believed to be correlated with the relief of migraine headache. The other hypothesis suggests that activation of 5-HT₁ receptors on perivascular fibres of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. These theories are not mutually exclusive.
Experimental data from animal studies show that sumatriptan also activates 5-HT₁ receptors on peripheral terminals of the trigeminal nerve, which innervates cranial blood vessels. This causes the inhibition of neuropeptide release. It is thought that such an action may contribute to the anti-migraine action of sumatriptan in humans.
Cardiovascular Effects: In vitro studies in human isolated epicardial coronary arteries suggest that the predominant contractile effect of 5-HT is mediated via 5-HT₂ receptors. However, 5-HT₁ receptors also contribute to some degree to the contractile effect seen. Transient increases in systolic and diastolic blood pressure (up to 20 mmHg) of rapid onset (within minutes), have occurred after intravenous administration of up to 64 μg/kg (3.2 mg for 50 kg subject) to healthy volunteers. These changes were not dose related and returned to normal within 10-15 minutes. Following oral administration of 200 mg or intranasal administration of 40 mg, however, mean peak increases in blood pressure were smaller and of slower onset than after intravenous or subcutaneous administration.
Pharmacodynamics: Significant relief begins about 10-15 minutes following subcutaneous injection, 15 minutes following intranasal administration and 30 minutes following oral administration.
Clinical Trials: Comparative Bioavailability Studies: A two-way crossover, single dose, fasting, comparative bioavailability study of pms-SUMATRIPTAN 100 mg tablets was performed versus GlaxoSmithKline, IMITREX 100 mg Tablets. The study was conducted in 24 healthy fasted subjects. There were no withdrawals. Bioavailability data were measured and the results are summarized in the following table: See Table 1.

Click on icon to see table/diagram/image

Migraine: The efficacy of sumatriptan succinate tablets for the treatment of migraine was established in four multicentre, randomized, placebo-controlled studies. Patients enrolled and treated in these studies were primarily female (84%), Caucasian (98%) and with a mean age of 40 years (range of 18 to 65 years). Patients were instructed to treat a moderate to severe headache. In Study 2, up to three doses were permitted to treat a single attack within a 24-hour period, non-responders could take a second dose at two hours, while any recurrence of migraine could be treated with a third dose. Studies 1, 3 and 4 were designed to allow for the treatment of up to three attacks.
Headache relief at two hours was statistically significantly greater for all sumatriptan succinate groups when compared to placebo (see Table 2).

Click on icon to see table/diagram/image

In study 4, the 50 mg (p=0.002) and 100 mg (p=0.003) groups had significantly more patients experience headache relief compared to the 25 mg group at 2 hours.
For patients with migraine-associated nausea, photophobia and/or phonophobia at baseline, there was a decreased incidence of these symptoms following administration of sumatriptan succinate tablets compared to placebo.
Menstrually-Associated Migraine: Two multicentre, randomized, placebo-controlled studies evaluated sumatriptan succinate 50 mg and 100 mg tablets administered during the mild phase of a menstrually-associated migraine attack. A total of 816 subjects with a mean age of 37 (18-65 years of age), with at least a 1-year history of migraine, and a 6-month history of regularly occurring MAM, were enrolled and treated. MAM was defined as any migraine beginning on Day-2, to +4 with day 1 = the first day of flow. Patients were instructed to treat a single mild, moderate or severe headache within one hour of mild pain onset.
A statistically significantly higher proportion of patients following sumatriptan succinate 50 mg and 100 mg achieved pain-free status at 2 hours post-dose compared with placebo in the treatment of menstrually-associated migraine (see Table 3).

Click on icon to see table/diagram/image

For patients with migraine-associated nausea, photophobia and/or phonophobia at baseline, there was a decreased incidence of these symptoms following administration of sumatriptan succinate compared to placebo.
Detailed Pharmacology: Animal Pharmacodynamics: The action of sumatriptan has been studied in a range of isolated preparations in vitro, all known to contain different 5-HT receptor subtypes.
In Beagle dog isolated saphenous vein known to contain 5-HT₁ receptors, sumatriptan had a mean EC₅₀² of 302 nM, while 5-HT had an EC₅₀ of 44 nM.
²molar concentrations required to produce 50% of the maximum response.
In cat isolated saphenous vein, sumatriptan (concentrations of up to 10 μM) had no activity on 5-HT₁ receptors, suggesting that sumatriptan is a highly selective agonist at some, but not all, 5-HT₁ receptors. The contrasting action of sumatriptan at these receptor sites in the Beagle dog and cat isolated saphenous veins provides evidence that 5-HT₁ receptors are heterogeneous.
Sumatriptan displayed virtually no activity at 5-HT₂ receptors mediating contraction of the rabbit isolated aorta (concentrations up to 50 μM) and at 5-HT₃ receptors mediating depolarization of the rat isolated vagus nerve (concentrations up to 100 μM).
The selectivity of sumatriptan was further confirmed by studies in dog isolated saphenous vein, and in dog and primate isolated basilar artery. In these assays sumatriptan was resistant to the selective 5-HT₂ and 5-HT₃ receptor antagonists, ketanserin and MDL72222, respectively. Radioligand binding studies provide yet additional support for the high degree of specificity of sumatriptan. Sumatriptan was shown to have a high affinity for some 5-HT₁ binding sites, notably the 5-HT_1D subtype, and no significant affinity for other neurotransmitter binding sites such as, 5-HT_1A, 5-HT_1C, 5-HT₂, 5-HT₃, alpha₁, alpha₂, beta₁, dopamine D₁ and D₂, muscarinic and benzodiazepine receptors. In the human isolated basilar artery, methiothepin specifically and equally antagonized the contractile effects of both 5-HT and sumatriptan, suggesting that sumatriptan and 5-HT contract this artery by activating the same receptor type. This receptor appears to be identical to the 5-HT₁ receptor which mediates contraction of the dog isolated saphenous vein and cerebral blood vessels in both the dog and primate.
Sumatriptan selectively reduced the extravasation of plasma proteins in the dura mater of rats and guinea pigs, in response to trigeminal nerve stimulation.
Although an inhibitory effect on neurotransmitter release from trigeminal nerve endings is implicated, the action of sumatriptan would still predominantly involve a direct vasoconstrictive action on dural blood vessels, which could be expected to inhibit extravasation. In fact, such a vasoconstrictive action during a migraine attack could also increase the threshold for activating perivascular nerve afferents by reducing pressure on edematous pain-sensitive vessels within the cranium.
The major metabolite of sumatriptan in humans and other animal species, GR49336, has no pharmacological activity at 5-HT₁ receptors or other vascular 5-HT receptor subtypes.
Sumatriptan (1 to 1000 μg/kg, iv) produced a selective long-lasting and dose-dependent decrease in carotid arterial blood flow, in vivo (anaesthetized Beagles), with little or no change in arterial blood pressure. The dose of sumatriptan producing 50% of its maximum vasoconstrictor action was 39 ± 8 μg/kg, iv. Maximal vasoconstrictor responses were achieved with intravenous doses between 300 to 1000 μg/kg.
The vasoconstrictor action of sumatriptan in the carotid arterial circulation of anesthetized Beagles is mediated by the activation of 5-HT₁ receptors since it was antagonized by methiothepin, a selective 5-HT₁ receptor blocker.
Sumatriptan (30 to 1000 μg/kg, iv) produced a dose-dependent reduction in the proportion of cardiac output passing through arteriovenous anastomoses (AVAs) in anaesthetized cats.
At doses up to 1000 μg/kg iv, sumatriptan had little effect upon vascular resistance in a variety of other vascular beds. In contrast, the administration of ergotamine (30 μg/kg) caused marked increases in vasoconstriction in most vascular beds examined.
Sumatriptan did not modify efferent vagal activity by either a central action or by interference with cholinergic neurotransmission from vagal nerve endings in the myocardium of anaesthetized cats.
It had no antinociceptive effects in rodents, and is, therefore, unlikely that its effectiveness in alleviating migraine headache is due to a generalized analgesic action.
In conscious monkeys, at cumulative doses of up to 1000 μg/kg, there were no significant effects on arterial blood pressure, heart rate, ECG or respiratory rate that could be attributed to the intravenous administration of sumatriptan.
Sumatriptan up to 1 mg/kg had little or no effect upon either pulmonary artery or esophageal pressure in Beagle dogs. There was also little or no effect upon total peripheral resistance, and only a slight increase in cardiac output and stroke volume.
In the rat, sumatriptan (1 and 10 mg/kg, ip) caused a dose-related increase in the rate of gastric emptying, the magnitude of this effect being comparable with that obtained with metoclopramide at doses of 5 to 20 mg/kg, ip.
Human Pharmacodynamics: Administration of subcutaneous sumatriptan 6 mg twice daily for 5 days to healthy subjects caused slight increases in mean systolic and diastolic blood pressures (6-8 mmHg) while heart rate decreased slightly (1-7 bpm).
Vasopressor effects were also evident following oral administration, with mean peak increases being somewhat smaller and of slower onset than after parenteral administration. A single oral dose of 200 mg sumatriptan caused significant increases in both systolic and diastolic blood pressures (16 mmHg and 5 mmHg, respectively); however, further dosing (200 mg three times daily for a further 7 days) did not cause any additional vasopressor effects.
In hypertensive patients with common or classical migraine, small, transient increases in both systolic and diastolic blood pressure (maximum mean increase: 6/6 mmHg) occurred shortly after subcutaneous doses of 6 mg, but resolved within 60 minutes. A dose-related increase of 14 mmHg in systolic blood pressure was found in elderly patients given 200 mg oral sumatriptan.
Sumatriptan had no effect on cardiac function in migraine patients when given as a 64 μg/kg intravenous infusion. Exercise tests were performed after each infusion showing that sumatriptan had no effect on left ventricular ejection fraction either at rest or after exercise, and no differences were noted between placebo and sumatriptan.
Pharmacokinetics: Pharmacokinetic parameters following oral administration is shown in Table 4.
Inter-patient and intra-patient variability was noted in most pharmacokinetic parameters assessed. (See Table 4.)

Click on icon to see table/diagram/image

Absorption/Metabolism: Sumatriptan is rapidly absorbed after oral administration. The low oral bioavailability is primarily due to metabolism (hepatic and pre-systemic) and partly due to incomplete absorption. The oral absorption of sumatriptan is not significantly affected either during migraine attacks or by food.
In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme. In studies conducted in a limited number of patients, MAO inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure.
Excretion: Non-renal clearance of sumatriptan accounts for about 80% of the total clearance. The major metabolite, the indole acetic acid analogue of sumatriptan, is mainly excreted in the urine where it is present as a free acid (35%) and the glucuronide conjugate (11%). It has no known 5-HT₁ or 5-HT₂ activity. Minor metabolites have not been identified.
Special Populations and Conditions: Geriatrics: No differences have been observed between the pharmacokinetic parameters in healthy elderly volunteers and those in younger volunteers (less than 65 years old).
Animal Pharmacokinetics: Absorption of radiolabelled drug-related material following single-dose oral administration of sumatriptan was both rapid and extensive in mice, rats, rabbits and dogs. Oral bioavailabilities of 37% in rat (5 mg/kg), 23% in rabbit (5 mg/kg) and 58% in dog (I mg/kg) indicate that first-pass metabolism is moderate to high in these species. In dogs, this was supported by low metabolic clearance relative to hepatic blood flow. Following intravenous administration, the parent compound was rapidly eliminated from the plasma of mice, rats and rabbits (t_1/2 ≤ 1.2 h) and less rapidly in dogs (t_1/2 = 2.1h). Active tubular secretion of sumatriptan occurred in the kidneys of rats and rabbits but not in the dog, where clearance was primarily metabolic.
The repeat-dose pharmacokinetics of sumatriptan in the mouse, rat, rabbit and dog were generally consistent with the single-dose data. Plasma levels attained in these species showed that sumatriptan concentrations were linearly-related to oral doses up to 160 mg/kg in mice, 200 mg/kg in rats (subcutaneous doses up to 25 mg/kg), 400 mg/kg in rabbits and 100 mg/kg in dogs (subcutaneous doses up to 24 mg/kg).
Following intranasal administration to the rat or dog, plasma concentrations of sumatriptan peaked at approximately 30 minutes; in the monkey it peaked at 15 minutes. A second peak was observed in some animals at 90 to 120 minutes, suggesting absorption of a swallowed portion of the dose.
The maximum concentrations of sumatriptan detected in plasma following oral or subcutaneous administration to dogs were 35- and 75-fold higher, respectively, than were measured in human plasma following standard therapeutic doses.
There was no evidence of accumulation or enzyme inhibition/induction in any of the species studied.
Radioactive drug-related material was widely distributed throughout the body following both oral and intravenous administration of radiolabelled sumatriptan. Transfer into the central nervous system was limited.
Drug-related material was cleared rapidly from all tissues with the exception of the eye in which it appeared to be bound to the melanin in the uveal tract.
The binding of sumatriptan to plasma proteins over the concentration range 10 to 1000 ng/mL was low, 21% or less, in all species studied. Erythrocyte-associated ¹⁴C-GR43175 was reversibly bound.
Placental transfer studies in rat and rabbit showed that in both species the fetuses were exposed to low levels of drug-related material. Sumatriptan and drug-related material were secreted into the milk of lactating rats and were present at higher concentrations than those seen in maternal plasma.
Following oral administration to the rabbit and dog, and intravenous administration to the dog, and intranasal administration to the rat and dog, the indole acetic acid derivative GR49336 was the major metabolite formed.
This metabolite was also a major component in the urine of rats after both oral and intravenous and intranasal administration and in rabbits after intravenous administration, indicating that oxidative deamination is the major metabolic pathway in all animal species studied.
Metabolism of the methylaminosulphonylmethyl side chain resulting in the formation of an N-demethylated derivative of sumatriptan was apparent in the urine of the mouse, rat, and rabbit but not in the dog.
The major route of excretion was via the urine in the mouse, rabbit and dog following oral and intravenous administration and in the rat following intravenous dosing only.
Following oral administration to rats, the major route of excretion of drug-related material was via the feces.
Toxicology: Acute Toxicity: Administration of single oral doses of sumatriptan up to 2000 mg/kg in rats and 1200 mg/kg in mice was well tolerated.
Dogs also survived high oral doses of sumatriptan (500 mg/kg).
In subcutaneous studies, a dose of 2 mg/kg to rats was lethal. Dogs received subcutaneous doses of 20 and 100 mg/kg which were non-lethal. The reactions to treatment were similar irrespective of species or route of administration. Apart from local damage at the injection sites, there were no macroscopic or microscopic changes noted in any tissue (Table 5). (See Table 5.)

Click on icon to see table/diagram/image

Long Term Studies: Subacute toxicity studies were conducted for periods up to 6 weeks in RH rats. Sumatriptan was given orally (by gavage) at doses up to 500 mg/kg/day and given subcutaneously at doses up to 81 mg/kg/day.
Clinical signs observed following oral administration were generally minor and transient in nature and occurred predominantly at 500 mg/kg/day. These signs included post-dosing erythema, mydriasis, ataxia, salivation, subdued temperament, postural changes and moist eyes.
Reactions were similar in subcutaneous studies in rats receiving doses of sumatriptan up to 81 mg/kg/day. Local irritation at the injection site was accompanied by a marked inflammatory response, local necrosis, hemorrhage, infiltration, granulation tissue formation and local muscle degeneration and repair. These reactions were dose dependent.
In dogs administered oral sumatriptan (1 to 100 mg/kg/day) in studies up to 6 weeks, clinical signs observed included head shaking, scratching, salivation, trembling, agitated behaviour, vocalization, mydriasis and vasodilation. These effects were dose-related. The dogs also developed tachycardia lasting for several hours, often followed by bradycardia. No changes in ECG were detected.
Subcutaneous administration of sumatriptan (1 to 16 mg/kg/day) up to 6 weeks in dogs caused injection site reactions similar to the reactions described in rats.
Chronic toxicity studies were carried out for 24 weeks and 72 weeks in rats and 26 and 60 weeks in dogs.
In both the 24-week and 72-week studies in rats receiving sumatriptan doses of 5, 50 and 500 mg/kg/day orally, clinical signs were similar to those seen in previous oral toxicity studies in rats and were mild and transient in nature.
Animals of each sex receiving 50 and 500 mg/kg/day gained weight more rapidly than controls. This was considered to be related to increased food consumption.
Small reductions in cholesterol levels were frequently noted at 500 mg/kg/day. As well, dose-related increases in urine-specific gravity were seen throughout the 72-week study at 500 mg/kg/day. These increases were of no toxicological significance. Cessation of treatment showed good evidence of recovery.
There were no macroscopic or histological treatment-related findings in any of the organs in either study.
A long term repeat-dose subcutaneous toxicity study of 24 weeks duration was performed in RH rats receiving sumatriptan at doses of 1, 8 and 64 mg/kg/day.
There was occasional temporary appearance of masses at the injection sites in the animals receiving the highest dose of sumatriptan. Evidence of injection site injury was also apparent in the recovery animals. Rats in this group showed signs of neutrophilia and lymphocytosis.
Injection site reactions in animals in the high-dose group were similar to those reported during previous toxicity studies.
Studies of 26 and 60 weeks at oral doses of 2, 10 and 50 mg/kg/day were performed in Beagle dogs.
A moderate increase in heart rate was observed in the intermediate (10 mg/kg/day) dose group (60 week study) and in the high (50 mg/kg/day) dose group (26 and 60 week studies). The increase lasted for up to 7 hours after dosing and a dose related decrease in heart rate was evident 24 hours after dosing, at 10 and 50 mg/kg/day. There were no changes in rhythm. Animals of either sex receiving 50 mg/kg/day showed slight reductions in body weight gain in both studies.
In the 60-week study, a dose-related incidence of transient changes was noted on the surface of the cornea. However, these changes were not considered to be treatment-related as evidenced by microscopic examination.
Organ weight analyses revealed significantly increased heart weights in all groups of treated females in the 26-week study. There were no treatment-related effects on organ weights in the 60-week study.
A long term repeat-dose subcutaneous study of 24 weeks duration was performed in the Beagle dog at doses of 1, 3.5 and 12 mg/kg/day. Injection site reactions included oedema, marked hemorrhage, moderate/chronic inflammation and minimal arteritis. Some minimal injection site changes were also seen in treated animals after a 5-week recovery period.
Transient dose-related changes in the precorneal tear film of treated dogs were observed. There was, however, no histological evidence of damage to the cornea or surrounding tissues.
Analysis of hematological parameters revealed a slight lowering of some red cell parameters in the high-dose (12 mg/kg/day) group. No reticulocyte response was evident. Although no effect on total leucocyte count was observed, lymphocyte numbers were generally lower and neutrophils were generally slightly higher at this dose level. The only change observed during the recovery period was a statistically significantly reduced hemoglobin level in the males.
Carcinogenicity: The carcinogenic potential of sumatriptan was evaluated in a 78-week oncogenicity study conducted in mice given oral doses of 10, 60 and 160 mg(base)/kg/day. There were two groups (102 mice each) given the vehicle only.
Tumours were found in more than half of the male mice and in less than half of the females across all groups. There was a statistically significant increase in the incidence of non-fatal hemolymphoreticular tumours observed in males at the dose of' 60 mg/kg/day group only when compared with controls. Since there was no dose relationship, this increase was considered to be of no toxicological significance. There was no evidence that administration of sumatriptan at any of the dose levels caused any alteration in the incidence of any specific tumours or non-neoplastic lesions.
A 104-week study was conducted in the Sprague-Dawley rat given oral doses of 10, 60 and 360 mg (base)/kg/day. Two control groups of 100 animals each were given vehicle control only.
There was a significant increase in the incidence of non-fatal adrenal medullary tumours (benign and malignant pheochromocytomas) in males given doses of 10 and 60 mg/kg/day and in males dosed at 360 mg/kg/day. A significant increase in the incidence of benign testicular interstitial (Leydig) cell tumours occurred when compared with controls. Adrenal medullary tumours also increased significantly in females dosed at 60 and 360 mg/kg/day. Comparison of both types of tumours with historical control data indicated that the observations were within the expected background range for the species and that long-term exposure to sumatriptan does not induce any treatment-related increases in the incidences of any tumours for the species tested.
Mutagenicity: Sumatriptan produced no detectable or reproducible mutagenic potential above that seen in controls, in studies conducted in vitro with mutant strains of Salmonella typhimurium, Escherichia coli, or Saccharomyces cerevisiae with or without a rat hepatic drug metabolizing enzyme system. In addition, no statistically significant clastogenic effects were seen in vitro using cultured human peripheral lymphocytes at a maximum dose of 1000 μg/mL in the presence of the rat hepatic drug metabolism enzyme system or in vivo in a rat micronucleus test, at a maximum dosage of 1000 mg/kg.
Sumatriptan showed only weak cytotoxic activity at the highest concentration of 5000 μg/mL tested in vitro with V-79 mammalian cells.
Reproduction and Teratology: In organogenesis studies, oral doses of up to 500 mg/kg/day in the rat were without adverse effects upon fetal parameters measured, but an oral dose of 1000 mg/kg/day in the rat, proved toxic to both dams and embryos.
Two oral organogenesis studies were conducted in rabbits, one using daily oral doses of 5, 25 or 100 mg/kg/day and the other using 5, 15 or 50 mg/kg/day. Sumatriptan was administered from days 8 to 20 of pregnancy.
In the first study, there were no adverse effects at the two lower doses. At the highest dose (100 mg/kg), there was a severe decrease in maternal body weight gain indicating that this dose is maternally toxic. A non-significant increase in post-implantation intra-uterine death from 8.3% in the untreated control group to 21.2% in the high-dose (background range in untreated control animals 1.7% to 15.2%) was observed. In addition there was an increased incidence of subtle variations in the position of certain blood vessels emanating from the aortic arch. In the untreated control these were present at 5.5% of fetuses (3 out of 10 litters affected). At the maternally toxic dose of 100 mg/kg, 23.1% of fetuses had these variations (4 out of 5 litters affected). This type of change is commonly found in untreated control animals (historical control incidence 17.5%; proportion of litters affected 44 out of 91), and does not compromise either health or survival.
In the second oral study, the findings were similar to those seen in the first study. There were no adverse effects at the two lower doses. At the highest dose (50 mg/kg), there was a severe decrease in maternal body weight gain. There were also various fetal effects ascribed to maternal toxicity. There was a slight reduction in mean fetal weight (37.7 g in control, 35.3 g at 50 mg/kg); small increases in the incidence of common skeletal variants (control incidence 8.8%; at 50 mg/kg 20.8%; background mean 6.2%; background range 1.3% - 13.3%) and again an increased incidence of positional changes of certain aortic arch blood vessels; (control incidence 12.8%, 3 out of 20 litters affected; at 50 mg/kg 25%, 10 out of 14 litters affected).
Placental transfer studies in pregnant rabbits have shown that sumatriptan can cross the placental barrier in small amounts. After a 5 mg/kg oral dose, 71.2 ng sumatriptan per gram of fetus was detected. The blood levels at this dose were 172 - 269 ng/mL. At the maternally toxic dose of 50 mg/kg in rabbits, blood levels reached 3180-6750 ng/mL.
Organogenesis studies conducted using intravenous doses of up to 12.5 mg/kg/day in rats revealed fused ribs at a dose of 2.5 mg/kg/day and rudimentary tail and dilatation of the renal pelvis at a dose of 12.5 mg/kg/day. The treatment had no adverse effects on either the dams or the fetuses and the malformations were considered unrelated to treatment since they are known to occur spontaneously in the control groups of the rat strain employed.
Rabbits were also studied using intravenous doses of up to 8.0 mg/kg/day which revealed no teratological response. However, in the first study a statistically significant dose-related increasing trend in prenatal mortality was seen due to apparent maternal toxicity. In the second study, using intravenous doses up to 2.0 mg/kg/day, no maternal toxicity or increased prenatal mortality were observed.
Fertility studies conducted in rats with oral doses of up to 500 mg/kg/day and subcutaneous doses of up to 60 mg/kg/day indicated that there were no adverse effects upon the reproductive performance of the treated, parental generation, or upon the growth and development of two successive untreated generations.
In peri- and postnatal studies conducted in rats given oral doses of up to 1000 mg/kg/day and subcutaneous doses of up to 81 mg/kg/day, no toxicological adverse effects that may have been relevant to the peri- and postnatal development of their offspring were seen. However, oral administration of 1000 mg/kg/day during periods of pregnancy and lactation resulted in a decrease in maternal and fetal body weight.
A comprehensive evaluation of the effects of sumatriptan on reproduction indicates that the compound is devoid of teratogenic potential in the rat. In addition, there were no adverse effects on fertility or postnatal development. In rabbit oral reproduction studies, there were increased incidences of variations in cervico-thoracic blood vessel configuration in the fetuses, but these were only seen at maternally toxic doses in which blood levels were in excess of 50 times those seen after therapeutic doses in humans. A direct association with sumatriptan treatment is considered unlikely but cannot be excluded. The relevance to humans is unknown.
Local Tolerance: The subcutaneous and intramuscular administration of 1 mL of a solution of sumatriptan (50 mg/mL) to rabbits produced no overt signs of irritancy and caused only slight necrotic changes in the deepest layers of the subcuticular muscle. While the subcutaneous lesions healed in a rapid and uncomplicated manner, the intramuscular lesions were moderately slow to heal.
At a lower concentration (2.5 mg/mL) no signs of subcutaneous or intramuscular irritancy were apparent.
In inhalation toxicity studies (dog, monkey), no irritants of the nasal passages or respiratory tract tissues were identified after intranasal administration of sumatriptan.
Skin and Eye Irritancy: Sumatriptan produced little or no irritant reaction when applied topically to the skin of guinea pigs and was a non-irritant in the rabbit eye.
Sumatriptan was shown to be devoid of detectable skin sensitizing potential in guinea pigs; subjected to a 12-day induction period (0.05 mL of a 10% solution, applied epicutaneously) prior to challenge with sumatriptan.
Dependence Liability: The physical dependence liability of sumatriptan was assessed in Cynomolgus monkeys at an oral dose of 5 mg/kg, the lowest tolerable dose causing mild to moderate CNS effects.
The behavioural changes observed upon withdrawal of sumatriptan were limited in number, sporadic, unsustained and not observed in all animals. It would appear that sumatriptan does not share with compounds such as opiates and benzodiazepines the ability to cause physical dependence.

Adults: pms-SUMATRIPTAN (sumatriptan succinate) is indicated for the acute treatment of migraine attacks with or without aura.
pms-SUMATRIPTAN is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, basilar, or ophthalmoplegic migraine (see Contraindications). Safety and efficacy have not been established for cluster headache, which is present in an older, predominantly male population.
Pediatrics (< 18 years of age): The safety and efficacy of sumatriptan succinate in children have not been established and its use in this age group is not recommended. (See Use in Children under Precautions.)
Geriatrics (> 65 years of age): Experience of the use of sumatriptan succinate in patients aged over 65 years is limited. Therefore the use of pms-SUMATRIPTAN in patients over 65 years is not recommended. (See Use in the Elderly under Precautions.)

Dosing Considerations: Adults: pms-SUMATRIPTAN (sumatriptan succinate) is indicated for the acute treatment of migraine headache with or without aura. pms-SUMATRIPTAN should not be used prophylactically. The safety of treating an average of more than four headaches in a 30-day period has not been established. The recommended dose of pms-SUMATRIPTAN should not be exceeded.
In addition to relieving the pain of migraine, sumatriptan has also been shown to be effective in relieving associated symptoms of migraine (nausea, vomiting, phonophobia, photophobia). Sumatriptan is equally effective when administered at any stage of a migraine attack. Long term (12-24 months) clinical studies with maximum recommended doses of sumatriptan indicate that there is no evidence of the development of tachyphylaxis, or medication-induced (rebound) headache.
Geriatrics: No differences have been observed between the pharmacokinetic parameters in healthy elderly volunteers compared with younger volunteers (less than 65 years old).
Pediatrics (patients under 18 years of age): The safety and efficacy of sumatriptan succinate in pediatrics have not been established and its use in this age group is not recommended. (See Use in Children under Precautions.)
Significant relief begins about 30 minutes following oral administration.
Recommended Dose and Dosage Adjustment: The minimal effective single adult dose of pms-SUMATRIPTAN tablets is 25 mg. The maximum recommended single dose is 100 mg. The optimal dose is a single 50 mg tablet. However, depending on individual patient's needs and response to treatment, some patients may require 100 mg. The recommended dose should not be exceeded.
Clinical trials have shown that approximately 50 - 75% of patients have headache relief within two hours after oral dosing with 100 mg, and that a further 15 - 25% have headache relief by 4 hours. Comparator studies have shown similar efficacy rates with the 50 mg and 100 mg tablets. There is evidence that doses of 50 and 100 mg may provide greater effect than 25 mg.
If the migraine headache returns, or if a patient has a partial response to the initial dose, the dose may be repeated after 2 hours. Not more than 200 mg should be taken in any 24-hour period.
If a patient does not respond to the first dose of pms-SUMATRIPTAN tablets, a second dose should not be taken for the same attack, as it is unlikely to be of clinical benefit. pms-SUMATRIPTAN may be taken to treat subsequent migraine attacks.
Special Populations: Adults with Mild to Moderate Hepatic Impairment: In patients with mild or moderate hepatic impairment, plasma sumatriptan concentrations up to two times those seen in healthy subjects have been observed. Therefore, a 25 mg dose (single tablet) may be considered in these patients (Child Pugh grade A or B) (see Hepatic Impairment under Precautions).
Adults with Severe Hepatic Impairment: Oral sumatriptan are contraindicated in patients with severe hepatic impairment (see Contraindications). pms-SUMATRIPTAN is contraindicated in patients with severe hepatic impairment (see Contraindications).
Administration: The tablet should be swallowed whole with water, not crushed, chewed or split.

There have been some reports of overdosage with sumatriptan succinate. Doses up to 400 mg orally were not associated with side effects other than those mentioned.
If overdosage with sumatriptan occurs, the patient should be monitored and standard supportive treatment applied as required. Toxicokinetic data are not available.
The effect of hemodialysis or peritoneal dialysis on the serum concentration of sumatriptan is unknown.

pms-SUMATRIPTAN is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases (e.g., atherosclerotic disease, congenital heart disease) should not receive pms-SUMATRIPTAN. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal's variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks (TIAs). Peripheral vascular disease includes, but is not limited to, ischemic bowel disease, or Raynaud's syndrome (see Cardiovascular under Precautions).
Because pms-SUMATRIPTAN may increase blood pressure, it is contraindicated in patients with uncontrolled or severe hypertension.
Concurrent administration of MAO inhibitors or use within 2 weeks of discontinuation of MAO inhibitor therapy is contraindicated (see Pharmacology: Pharmacokinetics: Absorption/Metabolism under Actions; Drug-Drug Interactions: MAO Inhibitors under Interactions).
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because pms-SUMATRIPTAN may also cause coronary vasospasm and these effects may be additive, the use of pms-SUMATRIPTAN within 24 hours before or after treatment with other 5-HT₁ receptor agonists, or ergotamine-containing drugs or their derivatives (e.g. dihydroergotamine, methysergide) is contraindicated.
pms-SUMATRIPTAN should not be administered to patients with severe hepatic impairment. (See Special Populations: Adults with Severe Hepatic Impairment under Dosage & Administration; Hepatic Impairment under Precautions.)
pms-SUMATRIPTAN is contraindicated in patients with hemiplegic, basilar, or ophthalmoplegic migraine.
pms-SUMATRIPTAN is contraindicated in patients with hypersensitivity to sumatriptan or to any of the ingredients of the formulation, or component of the container. For a complete listing, see Description.

General: pms-SUMATRIPTAN should only be used where a clear diagnosis of migraine has been established.
Cluster Headache: There is insufficient information on the efficacy and safety of sumatriptan succinate in the treatment of cluster headache, which is present in an older, predominantly male population. The need for prolonged use and the demand for repeated medication in this condition renders the dosing information inapplicable for cluster headache.
Psychomotor Impairment: Patients should be cautioned that drowsiness may occur as a result of treatment with pms-SUMATRIPTAN. They should be advised not to perform skilled tasks (e.g. driving or operating machinery) if drowsiness occurs.
Medication Overuse Headache: Overuse of acute headache treatments has been associated with the exacerbation of headache (medication overuse headache, MOH) in susceptible patients. Withdrawal of the treatment may be necessary.
Cardiovascular: Risk of Myocardial Ischemia and/or Infarction and Other Adverse Cardiac Events: Sumatriptan succinate has been associated with transient chest and/or neck pain, pressure, heaviness and tightness which may resemble angina pectoris. In rare cases, the symptoms have been identified as being the likely result of coronary vasospasm or myocardial ischemia. Rare cases of serious coronary events or arrhythmia have occurred following use of sumatriptan succinate. pms-SUMATRIPTAN should not be given to patients who have documented ischemic or vasospastic coronary artery disease (CAD) (see Contraindications). It is strongly recommended that pms-SUMATRIPTAN not be given to patients in whom unrecognized CAD is predicted by the presence of risk factors (e.g., hypertension, hyper-cholesterolemia, smoking, obesity, diabetes, strong family history of CAD, female who is surgically or physiologically postmenopausal, or male who is over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery vasospasm is unknown. If, during the cardiovascular evaluation, the patient's medical history or electrocardiographic investigations reveal findings indicative of, or consistent with, coronary artery vasospasm or myocardial ischemia, pms-SUMATRIPTAN should not be administered (see Contraindications).
For patients with risk factors predictive of CAD who are considered to have a satisfactory cardiovascular evaluation, the first dose of pms-SUMATRIPTAN should be administered in the setting of a physician's office or similar medically staffed and equipped facility. Because cardiac ischemia can occur in the absence of clinical symptoms, consideration should be given to obtaining electrocardiograms in patients with risk factors during the interval immediately following pms-SUMATRIPTAN administration on the first occasion of use.
However, an absence of drug-induced cardiovascular effects on the occasion of the initial dose does not preclude the possibility of such effects occurring with subsequent administrations.
Intermittent long term users of sumatriptan succinate who have or acquire risk factors predictive of CAD, as described previously, should receive periodic interval cardiovascular evaluations over the course of treatment.
If symptoms consistent with angina occur after the use of pms-SUMATRIPTAN, ECG evaluation should be carried out to look for ischemic changes.
The systematic approach described previously is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to pms-SUMATRIPTAN.
Discomfort in the chest, neck, throat and jaw (including pain, pressure, heaviness, tightness, dyspnea) has been reported after administration of sumatriptan succinate. Because 5-HT₁ agonists may cause coronary vasospasm, patients who experience signs or symptoms suggestive of angina following pms-SUMATRIPTAN should be evaluated for the presence of CAD or a predisposition to variant angina before receiving additional doses, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud's syndrome, following pms-SUMATRIPTAN should be evaluated for atherosclerosis or predisposition to vasospasm (see Contraindications; Clinical Trial Adverse Drug Reactions under Adverse Reactions).
Cardiac Events and Fatalities Associated with 5-HT₁-Agonists: pms-SUMATRIPTAN can cause coronary artery vasospasm. Serious adverse cardiac events, including acute myocardial infarction, life-threatening disturbances of cardiac rhythm, and death have been reported within a few hours following the administration of 5-HT₁ agonists. Considering the extent of use of 5-HT₁ agonists in patients with migraine, the incidence of these events is extremely low. The fact that some of these events have occurred in patients with no prior cardiac disease history and with documented absence of CAD, and the close proximity of the events to sumatriptan succinate use support the conclusion that some of these cases were caused by the drug. In many cases, however, where there has been known underlying coronary artery disease, the relationship is uncertain.
Premarketing Experience With Sumatriptan Succinate: Of 6348 patients with migraine who participated in premarketing controlled and uncontrolled clinical trials of oral sumatriptan succinate two experienced clinical adverse events shortly after receiving oral sumatriptan succinate that may have reflected coronary vasospasm. Neither of these adverse events was associated with a serious clinical outcome.
Among the more than 1900 patients with migraine who participated in premarketing controlled clinical trials of subcutaneous sumatriptan succinate, there were eight patients who sustained clinical events during or shortly after receiving sumatriptan succinate that may have reflected coronary artery vasospasm. Six of these eight patients had ECG changes consistent with transient ischemia, but without accompanying clinical symptoms or signs. Of these eight patients, four had either findings suggestive of CAD or risk factors predictive of CAD prior to study enrollment.
Among approximately 4,000 patients with migraine who participated in premarketing controlled and uncontrolled clinical trials of sumatriptan nasal spray, one patient experienced an asymptomatic subendocardial infarction possibly subsequent to a coronary vasospastic event.
Postmarketing Experience With Sumatriptan Succinate: Serious cardiovascular events, some resulting in death, have been reported in association with the use of sumatriptan succinate tablets. The uncontrolled nature of postmarketing surveillance, however, makes it impossible to determine definitively the proportion of the reported cases that were actually caused by sumatriptan succinate or to reliably assess causation in individual cases. On clinical grounds, the longer the latency between the administration of sumatriptan succinate and the onset of the clinical event, the less likely the association is to be causative. Accordingly, interest has focused on events beginning within 1 hour of the administration of sumatriptan succinate.
Cardiac events that have been observed to have onset within 1 hour of sumatriptan succinate administration include: coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation, cardiac arrest, and death.
Some of these events occurred in patients who had no findings of CAD and appear to represent consequences of coronary artery vasospasm. However, among reports from the USA of serious cardiac events occurring within 1 hour of sumatriptan succinate administration, almost all of the patients had risk factors predictive of CAD and the presence of significant underlying CAD was established in most cases (see Contraindications).
Cerebrovascular Events and Fatalities with 5-HT₁ Agonists: Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with oral sumatriptan succinate and some have resulted in fatalities. The relationship of sumatriptan succinate to these events is uncertain. In a number of cases, it appears possible that the cerebrovascular events were primary, sumatriptan succinate having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine when they were not. Before treating migraine headaches with pms-Sumatriptan in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. If a patient does not respond to the first dose, the opportunity should be taken to review the diagnosis before a second dose is given. It should also be noted that patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, TIA).
Special Cardiovascular Pharmacology Studies: In subjects (n=10) with suspected coronary artery disease undergoing angiography, a 5-HT₁ agonist at a subcutaneous dose of 1.5 mg produced an 8% increase in aortic blood pressure, an 18% increase in pulmonary artery blood pressure, and an 8% increase in systemic vascular resistance. In addition, mild chest pain or tightness was reported by four subjects. Clinically significant increases in blood pressure were experienced by three of the subjects (two of whom also had chest pain/discomfort). Diagnostic angiogram results revealed that 9 subjects had normal coronary arteries and 1 had insignificant coronary artery disease.
In an additional study with this same drug, migraine patients (n=35) free of cardiovascular disease were subjected to assessments of myocardial perfusion by positron emission tomography while receiving a subcutaneous 1.5 mg dose in the absence of a migraine attack. Reduced coronary vasodilatory reserve (~10%), increase in coronary resistance (~20%), and decrease in hyperemic myocardial blood flow (~10%) were noted. The relevance of these finding to the use of the recommended oral doses of this 5-HT₁ agonist is not known.
Similar studies have not been done with sumatriptan succinate. However, owing to the common pharmacodynamic actions of 5-HT₁ agonists, the possibility of cardiovascular effects of the nature described previously should be considered for any agent of this pharmacological class.
Other Vasospasm-Related Events: 5-HT₁ agonists may cause vasospastic reactions other than coronary artery vasospasm. Extensive post-market experience has shown the use of sumatriptan succinate to be associated with rare occurrences of peripheral vascular ischemia and colonic ischemia with abdominal pain and bloody diarrhea, and in isolated cases there was no previous history or concomitant medications.
Increase in Blood Pressure: Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients with and without a history of hypertension. pms-SUMATRIPTAN is contraindicated in patients with uncontrolled or severe hypertension (see Contraindications). In patients with controlled hypertension, pms-SUMATRIPTAN should be administered with caution, as transient increases in blood pressure and peripheral vascular resistance have been observed in a small portion of patients.
Immune: Rare hypersensitivity (anaphylaxis/anaphylactoid) reactions may occur in patients receiving 5-HT₁ agonists such as pms-SUMATRIPTAN. Such reactions can be life threatening or fatal. In general, hypersensitivity reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens (see Contraindications). Owing to the possibility of cross-reactive hypersensitivity reactions, pms-SUMATRIPTAN should not be used in patients having a history of hypersensitivity to chemically related 5-HT₁ receptor agonists. There have been reports of patients with known hypersensitivity to sulphonamides exhibiting an allergic reaction following administration of sumatriptan succinate. Reactions ranged from cutaneous hypersensitivity to anaphylaxis.
Neurologic: Care should be taken to exclude other potentially serious neurologic conditions before treating headache in patients not previously diagnosed with migraine headache or who experience a headache that is atypical for them. There have been rare reports where patients received 5-HT₁ agonists for severe headaches that were subsequently shown to have been secondary to an evolving neurologic lesion. For newly diagnosed patients or patients presenting with atypical symptoms, the diagnosis of migraine should be reconsidered if no response is seen after the first dose of pms-SUMATRIPTAN.
Seizures: Caution should be observed if pms-SUMATRIPTAN is to be used in patients with a history of seizures or other risk factors, such as structural brain lesions, which lower the convulsion threshold. There have also been rare post-market reports of seizures following administration of sumatriptan succinate in patients without risk factors or previous history of seizures. (See Post-Market Adverse Drug Reactions: Nervous System Disorders under Adverse Reactions.)
Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) and Serotonin Syndrome: Cases of life-threatening serotonin syndrome have been reported during combined use of selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans. If concomitant treatment with pms-SUMATRIPTAN and SSRIs (e.g., fluoxetine, paroxetine, sertraline) or SNRIs (e.g., venlafaxine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) (see Drug-Drug Interactions: Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) under Interactions).
Ophthalmologic: Binding to Melanin Containing Tissues: In rats treated with a single subcutaneous dose (0.5 mg/kg) or oral dose (2 mg/kg) of radiolabeled sumatriptan, the elimination half life of radioactivity from the eye was 15 and 23 days, respectively, suggesting that sumatriptan and/or its metabolites bind to the melanin of the eye. Because there could be an accumulation in melanin rich tissues over time, this raises the possibility that sumatriptan could cause toxicity in these tissues after extended use. However, no effects on the retina related to treatment with sumatriptan were noted in any of the oral or subcutaneous toxicity studies. Although no systematic monitoring of ophthalmologic function was undertaken in clinical trials, and no specific recommendations for ophthalmologic monitoring are offered, prescribers should be aware of the possibility of long term ophthalmologic effects.
Hepatic Impairment: The effect of hepatic impairment on the efficacy and safety of sumatriptan succinate has not been evaluated; however, the pharmacokinetic profile of sumatriptan in patients with moderate¹ hepatic impairment (Child Pugh B) shows that these patients, following an oral dose of 50 mg, have much higher plasma sumatriptan concentrations than healthy subjects (Table 6). Therefore, an oral dose of 25 mg may be considered in patients with mild or moderate hepatic impairment. (See Special Populations: Adults with Mild to Moderate Hepatic Impairment under Dosage & Administration.) (See Table 6.)

Click on icon to see table/diagram/image

¹Assessed by aminopyrine breath test (>0.2-0.4 scaling units).
The pharmacokinetic parameters of 6 mg subcutaneous sumatriptan do not differ statistically between normal volunteers and moderately hepatically impaired subjects (Child Pugh B). All formulations of sumatriptan are contraindicated in patients with severe hepatic impairment (see Special Populations: Adults with Severe Hepatic Impairment under Dosage & Administration; Contraindications).
Renal: The effects of renal impairment on the efficacy and safety of sumatriptan succinate have not been evaluated. Therefore, pms-SUMATRIPTAN is not recommended in this patient population.
Monitoring and Laboratory Tests: No specific laboratory tests are recommended for monitoring patients prior to and/or after treatment with sumatriptan succinate.
Use in Children: The safety and efficacy of sumatriptan succinate in children (<18 years of age) has not been established and its use in this age group is not recommended.
Use in the Elderly: Experience of the use of sumatriptan succinate in patients aged over 65 years is limited. Therefore the use of pms-SUMATRIPTAN in patients over 65 years is not recommended.

Pregnant Women: Reproduction studies, performed in rats, have not revealed any evidence of impaired fertility, teratogenicity, or postnatal development due to sumatriptan succinate. Reproduction studies, performed in rabbits by the oral route, have shown increased incidence of variations in cervico-thoracic blood vessel configuration in the fetuses. These effects were only seen at the highest dose tested, which affected weight gain in the dams, and at which blood levels were in excess of 50 times those seen in humans after therapeutic doses. A direct association with sumatriptan succinate treatment is considered unlikely but cannot be excluded.
Post-marketing data from multiple prospective pregnancy registries have documented the pregnancy outcomes in approximately 1,100 women exposed to sumatriptan. At this time, there is insufficient information to draw conclusions. Therefore, the use of pms-SUMATRIPTAN is not recommended in pregnancy and it should be used only if the potential benefit to the mother justifies the potential risk to the fetus.
In a rat fertility study, oral doses of sumatriptan succinate resulting in plasma levels approximately 150 times those seen in humans after a 6 mg subcutaneous dose and approximately 200 times those seen in humans after a 100 mg oral dose were associated with a reduction in the success of insemination. This effect did not occur during a subcutaneous study, where maximum plasma levels achieved approximately 100 times those in humans by the subcutaneous route and approximately 150 times those in humans by the oral route.
Nursing Women: Sumatriptan is excreted in human breast milk. Therefore, caution is advised when administering pms-SUMATRIPTAN to nursing women. Infant exposure can be minimized by avoiding breast-feeding for 24 hours after treatment.

Serious cardiac events, including some that have been fatal, have occurred following the use of 5-HT₁ agonists. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (see Contraindications; Cardiovascular under Precautions).
Clinical Trial Adverse Drug Reactions: Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.
Experience in Controlled Clinical Trials with sumatriptan succinate: Typical 5-HT₁ Agonist Adverse Reactions: As with other 5-HT₁ agonists, sumatriptan succinate has been associated with sensations of heaviness, pressure, tightness or pain, which may be intense. These may occur in any part of the body including the chest, throat, neck, jaw and upper limb.
Acute Safety: In placebo-controlled migraine trials, 3095 patients received at least one dose of oral sumatriptan succinate. Table 7 lists adverse events occurring at an incidence of 1% or more in any of the sumatriptan succinate dose groups and that occurred at a higher incidence than in the placebo groups. (See Table 7.)

Click on icon to see table/diagram/image

Sumatriptan succinate is generally well tolerated. Most of the events were transient in nature and resolved within 2 hours of oral administration.
Other Events Observed During Clinical Trials: Minor disturbances of liver function tests have occasionally been observed with sumatriptan treatment. There is no evidence that clinically significant abnormalities occurred more frequently with sumatriptan than with placebo.
Dyspnea has commonly been observed following sumatriptan treatment.
Post-Market Adverse Drug Reactions: The following enumerates potentially important adverse events that have occurred in clinical practice and that have been reported spontaneously to various surveillance systems. The events enumerated represent reports arising from both domestic and nondomestic use of sumatriptan. These events do not include those already listed previously. Because the reports cite events reported spontaneously from worldwide postmarketing experience, the frequency of such events and the role of sumatriptan in their causation cannot be reliably determined.
Cardiac Disorders: Bradycardia, tachycardia, palpitations, cardiac arrhythmias, transient ischaemic ECG changes, coronary artery vasospasm, angina, myocardial infarction (see Contraindications; Cardiovascular under Precautions).
Ophthalmologic Disorders: Patients treated with sumatriptan succinate rarely exhibit visual disorders like flickering and diplopia. Additionally, cases of reduced vision have been observed. Very rarely, both transient and permanent loss of vision have occurred. These occurrences have included reports of retinal vascular occlusion, ocular venous thrombosis, vasospasm of the eye and ischemic optic neuropathy. Visual disorders may also occur during a migraine attack itself.
Gastrointestinal Disorders: Colonic ischemia (see Cardiovascular: Other Vasospasm-Related Events under Precautions).
Immune System Disorders: Hypersensitivity reactions ranging from cutaneous hypersensitivity to anaphylaxis (see Immune under Precautions).
Nervous System Disorders: Seizures, although some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures there are also reports in patients where no such predisposing factors are apparent (see Neurologic: Seizures under Precautions).
There have been very rare reports of dystonia and related extrapyramidal disorders, such as choreoathetoid movement, akathisia, parkinsonism and akinesia following both subcutaneous and oral treatments of sumatriptan succinate. Patients with previous history of drug related dystonia and patients taking medications recognised to be associated with movement disorders such as SSRIs, may be at higher risk.
Nystagmus, scotoma.
Vascular Disorders: Hypotension, Raynaud's phenomenon, peripheral vascular ischemia (see Contraindications; Cardiovascular: Other Vasospasm-Related Events and Increase in Blood Pressure under Precautions).

Drug-Drug Interactions: Single-dose pharmacokinetic drug interaction studies have not shown evidence of interactions with propranolol, flunarizine, pizotifen or alcohol. Multiple-dose interaction studies have not been performed.
Ergot-Containing Drugs: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis for these effects being additive, ergot-containing or ergot-type medications (like dihydroergotamine or methysergide) are contraindicated within 24 hours of pms-SUMATRIPTAN administration (see Contraindications).
MAO Inhibitors: In studies conducted in a limited number of patients, MAO inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. Therefore, the use of pms-SUMATRIPTAN in patients receiving MAO inhibitors is contraindicated (see Pharmacology: Pharmacokinetics: Absorption/Metabolism under Actions; Contraindications).
Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Cases of life-threatening serotonin syndrome have been reported during combined use of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans (see Neurologic: Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) and Serotonin Syndrome under Precautions).
Other 5-HT₁ agonists: The administration of sumatriptan succinate with other 5-HT₁ agonists has not been evaluated in migraine patients. As an increased risk of coronary vasospasm is a theoretical possibility with coadministration of 5-HT₁ agonists, use of these drugs within 24 hours of each other is contraindicated.
Drug-Laboratory Test Interactions: Sumatriptan succinate is not known to interfere with commonly employed clinical laboratory tests.

pms-SUMATRIPTAN Tablets should be stored below 25°C.

Antimigraine Preparations

N02CC01 - sumatriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.

P₁S₁S₃